Alamro M, Bidmos FA, Chan H, Oldfield NJ, Newton E, Bai X, Aidley J, Care R, et al. 2014 Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage. Infect. Immun.
82 2472–2484
Article
PubMed
PubMed Central
Google Scholar
Alexander HL, Richardson AR and Stojiljkovic I 2004 Natural transformation and phase variation modulation in Neisseria meningitidis. Mol. Microbiol.
52 771–783
CAS
Article
PubMed
Google Scholar
Bayliss CD, Hoe JC, Makepeace K, Martin P, Hood DW and Moxon ER 2008 Neisseria meningitidis escape from the bactericidal activity of a monoclonal antibody is mediated by phase variation of lgtG and enhanced by a mutator phenotype. Infect. Immun.
76 5038–5048
Bonvehi P, Boutriau D, Casellas J, Weynants V, Feron C and Poolman J 2010 Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin. Vaccine Immunol.
17 1460–1466
CAS
Article
PubMed
PubMed Central
Google Scholar
Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N, Richmond P and Poolman J 1999 Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine
17 2612–2619
De Bolle X, Bayliss CD, Field D, van de Ven T, Saunders NJ, Hood DW and Moxon ER 2000 The length of a tetranucleotide repeat tract in Haemophilus influenzae determines the phase variation rate of a gene with homology to type III DNA methyltransferases. Mol. Microbiol.
35 211–222
Article
PubMed
Google Scholar
de Jonge MI, Vidarsson G, van Dijken HH, Hoogerhout P, van Alphen L, Dankert J and van der Ley P 2003 Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis. Infect. Immun.
71 2331–2340
de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, et al. 2000 Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine
18 1456–1466
Finney M, Vaughan T, Taylor S, Hudson MJ, Pratt C, Wheeler JX, Vipond C, Feavers I, et al. 2007 Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on neisseria lactamica outer membrane vesicles. Hum. Vaccin.
4 23–30
Article
PubMed
Google Scholar
Gray-Owen SD 2003 Neisserial Opa proteins: impact on colonization, dissemination and immunity. Scand. J. Infect. Dis.
35 614–618
CAS
Article
PubMed
Google Scholar
Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, et al. 2012 The changing and dynamic epidemiology of meningococcal disease. Vaccine
30 B26–B36
Article
PubMed
Google Scholar
James JF and Swanson J 1978 Studies on gonococcus infection. XIII. Occurrence of color/opacity colonial variants in clinical cultures. Infect. Immun.
19 332–340
CAS
PubMed
PubMed Central
Google Scholar
Jerse AE, Cohen MS, Drown PM, Whicker LG, Isbey SF, Seifert HS and Cannon JG 1994 Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. J. Exp. Med.
179 911–920
CAS
Article
PubMed
Google Scholar
Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, et al. 2011 A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine
29 1413–1420
Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE 3rd, Schmiel DH, Pinto V, et al. 2010 A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine
28 6970–6976
Koeberling O, Giuntini S, Seubert A and Granoff DM 2009 Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol.
16 156–162
CAS
Article
PubMed
Google Scholar
Mackinnon FG, Cox AD, Plested JS, Tang CM, Makepeace K, Coull PA, Wright JC, Chalmers R, et al. 2002 Identification of a gene (lpt-3) required for the addition of phosphoethanolamine to the lipopolysaccharide inner core of Neisseria meningitidis and its role in mediating susceptibility to bactericidal killing and opsonophagocytosis. Mol. Microbiol.
43 931–943
Mandrell RE and Zollinger WD 1989 Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect. Immun.
57 1590–1598
CAS
PubMed
PubMed Central
Google Scholar
Martin P, Sun L, Hood DW and Moxon ER 2004 Involvement of genes of genome maintenance in the regulation of phase variation frequencies in Neisseria meningitidis. Microbiology
150 3001–3012
Mayer LW 1982 Rates in vitro changes of gonococcal colony opacity phenotypes. Infect. Immun.
37 481–485
CAS
PubMed
PubMed Central
Google Scholar
Pettersson A, Kortekaas J, Weynants VE, Voet P, Poolman JT, Bos MP and Tommassen J 2006 Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB. Vaccine
24 3545–3557
Richardson AR and Stojiljkovic I 2001 Mismatch repair and the regulation of phase variation in Neisseria meningitidis. Mol. Microbiol.
40 645–655
Richardson AR, Yu Z, Popovic T and Stojiljkovic I 2002 Mutator clones of Neisseria meningitidis in epidemic serogroup A disease. Proc. Natl. Acad. Sci. USA
99 6103–6107
Sadarangani M, Hoe JC, Callaghan MJ, Jones C, Chan H, Makepeace K, Daniels-Treffandier H, Deadman ME, et al. 2012 Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine. PLoS One
7 e51045
Sadarangani M and Pollard AJ 2010 Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect. Dis.
10 112–124
CAS
Article
PubMed
Google Scholar
Sadarangani M, Pollard AJ and Gray-Owen SD 2011 Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol. Rev.
35 498–514
CAS
Article
PubMed
Google Scholar
Saunders NJ, Moxon ER and Gravenor MB 2003 Mutation rates: estimating phase variation rates when fitness differences are present and their impact on population structure. Microbiology
149 485–495
Snyder LA, Butcher SA and Saunders NJ 2001 Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic Neisseria spp. Microbiology
147 2321–2332
Stern A, Brown M, Nickel P and Meyer TF 1986 Opacity genes in Neisseria gonorrhoeae: control of phase and antigenic variation. Cell
47 61–71
CAS
Article
PubMed
Google Scholar
Swanson J, Barrera O, Sola J and Boslego J 1988 Expression of outer membrane protein II by gonococci in experimental gonorrhea. J. Exp. Med.
168 2121–2129
CAS
Article
PubMed
Google Scholar
Tauseef I, Ali YM and Bayliss CD 2013 Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidis. Infect. Immun.
81 1374–1380
Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, Ketchum KA, Hood DW, et al. 2000 Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science
287 1809–1815
van den Dobbelsteen GP, van Dijken HH, Pillai S and van Alphen L 2007 Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine
25 2491–2496
Virji M, Makepeace K, Ferguson DJ, Achtman M and Moxon ER 1993 Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol. Microbiol.
10 499–510
CAS
Article
PubMed
Google Scholar
Warmlander S, Sponer JE, Sponer J and Leijon M 2002 The influence of the thymine C5 methyl group on spontaneous base pair breathing in DNA. J. Biol. Chem.
277 28491–28497
CAS
Article
PubMed
Google Scholar
Weynants V, Denoel P, Devos N, Janssens D, Feron C, Goraj K, Momin P, Monnom D, et al. 2009 Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun.
77 2084–2093
Weynants VE, Feron CM, Goraj KK, Bos MP, Denoel PA, Verlant VG, Tommassen J, Peak IR, et al. 2007 Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun.
75 5434–5442
World Health Organization 1998 Control of epidemic meningococcal disease. WHO practical guidelines 2nd edition (Geneva: World Health Organization)
Google Scholar
Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie JE 3rd, Moran EE, Brandt BL, Ionin B, et al. 2010 Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine
28 5057–5067